Skip to main content
Top
Published in: Clinical Research in Cardiology 1/2019

01-01-2019 | Original Paper

Follow-up of the first patients with a totally subcutaneous ICD in Germany from implantation till battery depletion

Authors: Markus Bettin, Benjamin Rath, Christian Ellermann, Patrick Leitz, Florian Reinke, Julia Köbe, Lars Eckardt, Gerrit Frommeyer

Published in: Clinical Research in Cardiology | Issue 1/2019

Login to get access

Abstract

Background

The subcutaneous ICD is a promising treatment option in patients at risk for sudden cardiac death. Approved in 2009, the first S-ICD® in Germany was implanted in June 2010. Although large prospective registry studies have shown safety and efficacy of the system, there is a lack of long-term data with regard to battery longevity of the S-ICD®. Therefore, we report follow-up of our first initial S-ICD® cases from implantation till battery depletion.

Materials and methods

All S-ICD® patients with device replacement for battery depletion in our large single-center S-ICD® registry were included in this study. Baseline characteristics, appropriate and inappropriate shocks, and complications were documented in a median follow-up of 75.9 ± 6.8 months.

Results

Twenty-eight patients with S-ICD® systems were included in this study. Of these patients, 21 were male and 7 were female, with an overall mean age of 41.9 ± 12.6 years. Primary prevention of sudden cardiac death was the indication in 19 patients (67.9%). Ventricular tachycardia was adequately terminated in two patients (7.1%). In 7 patients, non-sustained ventricular arrhythmias were not treated. A total of three inappropriate shocks occurred in three patients (10.7%). Mean time from implantation till battery depletion was 65.8 ± 8.1 months. Only one patient presented premature elective replacement criteria because of rapid battery depletion. No lead-related complication occurred during follow-up and no complications were seen regarding device replacement. In one patient (3.6%), the system was explanted without replacement due to patient’s preference.

Conclusion

The estimated battery longevity of S-ICD® of about 5 years was reached in all but one patient. Compared to larger S-ICD® registry studies, frequency of inappropriate shocks was relatively high in the initial S-ICD® cases. Both technological improvement as well as programming and operators’ experience have led to a reduction of complications. Replacement of the S-ICD® seems to be a safe and effective procedure.
Literature
1.
go back to reference Lambiase PD, Barr C, Theuns DA et al (2014) Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J 3 5(25):1657–1665CrossRef Lambiase PD, Barr C, Theuns DA et al (2014) Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J 3 5(25):1657–1665CrossRef
2.
go back to reference Weiss R, Knight BP, Gold MR et al (2013) Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation 128:944–953CrossRefPubMed Weiss R, Knight BP, Gold MR et al (2013) Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation 128:944–953CrossRefPubMed
3.
go back to reference Brouwer TF, Yilmaz D, Lindeboom R et al (2016) Long-term clinical outcomes of subcutaneous versus transvenous implantable defibrillator therapy. J Am Coll Cardiol 68:2047–2055CrossRefPubMed Brouwer TF, Yilmaz D, Lindeboom R et al (2016) Long-term clinical outcomes of subcutaneous versus transvenous implantable defibrillator therapy. J Am Coll Cardiol 68:2047–2055CrossRefPubMed
4.
go back to reference Bardy GH, Smith WM, Hood MA et al (2010) An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 363:36–44CrossRefPubMed Bardy GH, Smith WM, Hood MA et al (2010) An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 363:36–44CrossRefPubMed
5.
go back to reference Friedman DJ, Parzynski CS, Varosy PD et al (2016) Trends and in-hospital outcomes associated with adoption of the subcutaneous implantable cardioverter defibrillator in the United States. JAMA Cardiol 1:900–911CrossRefPubMedPubMedCentral Friedman DJ, Parzynski CS, Varosy PD et al (2016) Trends and in-hospital outcomes associated with adoption of the subcutaneous implantable cardioverter defibrillator in the United States. JAMA Cardiol 1:900–911CrossRefPubMedPubMedCentral
6.
go back to reference Priori SG, Blomström-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Europace 2015,17(11):1601–1687 Priori SG, Blomström-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Europace 2015,17(11):1601–1687
8.
go back to reference Theuns DA, Crozier IG, Barr CS et al (2015) Longevity of the subcutaneous implantable defibrillator. Long-term follow-up of the European Regulatory Trial Cohort. Circ Arrhythm Electrophysiol 8:1159–1163CrossRefPubMed Theuns DA, Crozier IG, Barr CS et al (2015) Longevity of the subcutaneous implantable defibrillator. Long-term follow-up of the European Regulatory Trial Cohort. Circ Arrhythm Electrophysiol 8:1159–1163CrossRefPubMed
9.
go back to reference Köbe J, Hucklenbroich K, Geisendörfer N et al (2017) Posttraumatic stress and quality of life with the totally subcutaneous compared to conventional cardioverter-defibrillator systems. Clin Res Cardiol 106:317–321CrossRefPubMed Köbe J, Hucklenbroich K, Geisendörfer N et al (2017) Posttraumatic stress and quality of life with the totally subcutaneous compared to conventional cardioverter-defibrillator systems. Clin Res Cardiol 106:317–321CrossRefPubMed
10.
go back to reference Healey JS, Hohnloser SH, Glikson M et al (2015) Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). Lancet 385:785–791CrossRefPubMed Healey JS, Hohnloser SH, Glikson M et al (2015) Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). Lancet 385:785–791CrossRefPubMed
11.
go back to reference Moss AJ, Schuger C, Beck CA et al (2012) Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 367:2275–2283CrossRefPubMed Moss AJ, Schuger C, Beck CA et al (2012) Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 367:2275–2283CrossRefPubMed
12.
go back to reference Frommeyer G, Dechering DG, Zumhagen S et al (2016) Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience. Clin Res Cardiol 105:89–93CrossRefPubMed Frommeyer G, Dechering DG, Zumhagen S et al (2016) Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience. Clin Res Cardiol 105:89–93CrossRefPubMed
13.
go back to reference Burke MC, Gold MR, Knight BP et al (2015) Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS registry. J Am Coll Cardiol 65:1605–1615CrossRefPubMed Burke MC, Gold MR, Knight BP et al (2015) Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS registry. J Am Coll Cardiol 65:1605–1615CrossRefPubMed
14.
go back to reference Knops RE, Brouwer TF, Barr CS et al (2016) The learning curve associated with the introduction of the subcutaneous implantable defibrillator. Europace 18:1010–1015CrossRefPubMed Knops RE, Brouwer TF, Barr CS et al (2016) The learning curve associated with the introduction of the subcutaneous implantable defibrillator. Europace 18:1010–1015CrossRefPubMed
15.
go back to reference Brisben AJ, Burke MC, Knight BP et al (2015) A new algorithm to reduce inappropriate therapy in the S-ICD system. J Cardiovasc Electrophysiol 26:417–423CrossRefPubMed Brisben AJ, Burke MC, Knight BP et al (2015) A new algorithm to reduce inappropriate therapy in the S-ICD system. J Cardiovasc Electrophysiol 26:417–423CrossRefPubMed
16.
go back to reference Kooiman KM, Knops RE, Olde Nordkamp L et al (2014) Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave overesensing can be prevented: Implications for management. Heart Rhythm 11:426–434CrossRefPubMed Kooiman KM, Knops RE, Olde Nordkamp L et al (2014) Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave overesensing can be prevented: Implications for management. Heart Rhythm 11:426–434CrossRefPubMed
Metadata
Title
Follow-up of the first patients with a totally subcutaneous ICD in Germany from implantation till battery depletion
Authors
Markus Bettin
Benjamin Rath
Christian Ellermann
Patrick Leitz
Florian Reinke
Julia Köbe
Lars Eckardt
Gerrit Frommeyer
Publication date
01-01-2019
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 1/2019
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-018-1296-1

Other articles of this Issue 1/2019

Clinical Research in Cardiology 1/2019 Go to the issue